Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial

Group IIA Secretory Phospholipase A 2 , Vascular Inflammation, and Incident Cardiovascular Disease

(2019) Akintunde O. Akinkuolie et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk

(2018) Kavisha Singh et al.   Journal of Thoracic Disease

Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults

(2018) Iona Y. Millwood et al.   JAMA Cardiology

Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies

(2017) Christian M. Madsen et al.   EUROPEAN HEART JOURNAL

Influence of HDL particles on cell-cholesterol efflux under various pathological conditions

(2017) Bela F. Asztalos et al.   JOURNAL OF LIPID RESEARCH

Diabetes-Invoked High-Density Lipoprotein and Its Association With Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus

(2016) Jia Teng Sun et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of serum amyloid A on the structure and antioxidant ability of high-density lipoprotein

(2016) M. Sato et al.   BIOSCIENCE REPORTS

HDL function is impaired in acute myocardial infarction independent of plasma HDL cholesterol levels

(2016) Wijtske Annema et al.   Journal of Clinical Lipidology

Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA

(2016) Shobini Jayaraman et al.   JOURNAL OF LIPID RESEARCH

High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions

(2016) Dennis T. Ko et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparing fluorescence-based cell-free assays for the assessment of antioxidative capacity of high-density lipoproteins

(2016) Fumiyoshi Tsunoda et al.   Lipids in Health and Disease

Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

(2016) Paolo Zanoni et al.   SCIENCE

GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation

(2015) J. D. Otvos et al.   CLINICAL CHEMISTRY

Impaired antioxidant HDL function is associated with premature myocardial infarction

(2015) Klaus Distelmaier et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Proteolysis of Apolipoprotein A-I by Secretory Phospholipase A2

(2014) Giorgio Cavigiolio et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease

(2014) C. Morgantini et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Heart Failure is Associated With Impaired Anti-Inflammatory and Antioxidant Properties of High-Density Lipoproteins

(2013) Juyong Brian Kim et al.   AMERICAN JOURNAL OF CARDIOLOGY

HDL anti-oxidant function associates with LDL level in young adults

(2013) Carrie V. Breton et al.   ATHEROSCLEROSIS

High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy

(2013) Samia Mora et al.   CIRCULATION

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk

(2013) Amit V. Khera et al.   CIRCULATION

Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy

(2013) Parin J. Patel et al.   EUROPEAN JOURNAL OF HEART FAILURE

Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis from the JUPITER Trial

(2012) P. M. Ridker et al.   CLINICAL CHEMISTRY

On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy

(2012) Samia Mora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events

(2012) Rachel H. Mackey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Anti-Oxidative Capacity of High-Density Lipoprotein Is Reduced in Acute Coronary Syndrome But Not in Stable Coronary Artery Disease

(2011) Parin J. Patel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis

(2011) Amit V. Khera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE